NOVEL ASSAY PLATFORM FOR ASESSING PROTEIN KINASE INHIBITORS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,261.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA141858-01
Award Id:
93588
Agency Tracking Number:
CA141858
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
10425 COGDILL RD., #300, KNOXVILLE, TN, 37932
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
015180610
Principal Investigator:
VAL GOLOVLEV
(865) 671-2166
GOLOVLEV@TDS.NET
Business Contact:
VAL GOLOVLEV
() -
golovlev@scien-tec.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of this SBIR project is to develop a new drug discovery platform for screening tyrosine kinase inhibitors. The main innovation of the proposed platform is the use of a multi-enzyme assay, which is able to measu re efficiency and identify inhibition mechanism in a single experiment in real-time using a small-volume sample. The proposed platform addresses the drawbacks of the existing methods by reducing the cost of reagents by ten times or more; by substantially r educing the assay time and significantly increasing the information yield of the drug screening process. The technology is adaptable to high through put format and has unique capabilities for identification and study allosteric kinase inhibitors, which pla y a central role in the development of new pharmaceuticals for treatment of cancer, inflammatory diseases, neural disorders, and metabolism problems. PUBLIC HEALTH RELEVANCE: Protein kinases represent one of the most promising groups of drug targets due to the vital role played by kinases in such pathological conditions as cancer, inflammatory diseases, neural disorders, and metabolism problems. Currently about 25% of all research spending on drug discovery and development is directed to new kinase inhibito rs with a special focus on the discovery of allosteric inhibitors, which have a higher inhibition efficiency, lower toxicity and longer duration of action. Yet, identification of new allosteric inhibitors is challenging and requires tedious kinetic and X-r ay diffraction studies, which are costly, labor intensive and too often are not carried out at the full extend. The technology under development in this SBIR project has a unique capability for identification and study allosteric kinase inhibitors and is a ble to provide more information quickly and at a lower cost.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government